Lilly’s donanemab slowed Alzheimer’s disease progression in Phase 2 trial: full data presented at AD/PD™ 2021 and published in NEJM
- Saturday, March 13, 2021, 7:03
- Finance
- Add a comment
INDIANAPOLIS, March 13, 2021 /PRNewswire/ — Phase 2 TRAILBLAZER-ALZ results presented today by Eli Lilly and Company (NYSE: LLY) at the 15th International Conference on Alzheimer’s & Parkinson Diseases™ 2021 (AD/PD™ 2021) held virtually March 9-14, 2021 and published simultaneously in…
About the Author
adminasapcorp has written 41562 stories on this site.